Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06437353
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-05-26
Brief Title:
Surufatinib Combined With CarboplatinPaclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Sponsor:
Anhui Provincial Cancer Hospital
Organization:
Anhui Provincial Cancer Hospital
Organization Data
Organization:
Anhui Provincial Cancer Hospital
Class:
OTHER
Study ID:
2024 No 047
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Anhui Provincial Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Bai-Rong Xia
Responsible Party Title:
Director of Gynecological Surgery
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Anhui Provincial Cancer Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Hutchison Medipharma Limited | INDUSTRY |